Rituximab
- Generic Name
- Rituximab
- Brand Names
- MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 174722-31-7
- Unique Ingredient Identifier
- 4F4X42SYQ6
- Background
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...
- Indication
Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...
- Associated Conditions
- Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)
- Associated Therapies
- -
Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-12-30
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193466
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-12-30
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193440
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 51
- Registration Number
- NCT00193479
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2015-01-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT00193492
- Locations
- 🇺🇸
Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸Oncology Hematology Care, Cincinnati, Ohio, United States
LMBA02 Protocol for Patients With a Burkitt Lymphoma
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2006-09-11
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 260
- Registration Number
- NCT00180882
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2006-09-11
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 40
- Registration Number
- NCT00180895
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-11-28
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 36
- Registration Number
- NCT00186628
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2005-09-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 150
- Registration Number
- NCT00168740
- Locations
- 🇺🇸
Hoag Hospital, Newport Beach, California, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois, United States
Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2005-09-15
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 430
- Registration Number
- NCT00169169
- Locations
- 🇫🇷
Hôpital Henri Mondor, Créteil, France
🇫🇷Hôpital Saint Louis, Paris, France
🇫🇷Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 50
- Registration Number
- NCT00169208
- Locations
- 🇫🇷
Service d'Hématologie Hôpital St Louis, Paris, France
🇫🇷Service de médecine D - Maladies du Sang CHU Angers, Angers, France
🇫🇷Service d'hématologie Institut Paoli Calmette, Marseille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.